NCT00026520已完成2 期
Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 94
研究概览
简要总结
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of the tumor. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining interferon alfa with thalidomide may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with thalidomide in treating patients who have stage IV melanoma.
详细描述
OBJECTIVES:
- Determine the 6-month progression-free survival rate in patients with stage IV melanoma treated with interferon alfa and thalidomide.
- Determine the confirmed and unconfirmed complete and partial response rates in patients with measurable disease treated with this regimen.
- Determine the quantitative and qualitative toxic effects of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive interferon alfa subcutaneously twice daily and oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses after documentation of CR.
Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed stage IV malignant melanoma
- •Surgically incurable disease
- •Measurable or evaluable disease
- •No brain metastases by CT scan or MRI
- •Prior brain metastases allowed only if completely resected and treated with whole brain radiotherapy
- •Must have received 1, and only 1, prior systemic therapy for metastatic disease
- •Chemotherapy, biologic/immunotherapy, hormonal therapy, or combination therapy
- •PATIENT CHARACTERISTICS:
- •Performance status:
- •Zubrod 0-2
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute neutrophil count at least 1,000/mm^3
- •Platelet count at least 75,000/mm^3
- •SGOT and/or SGPT no greater than 2.5 times upper limit of normal (ULN)
- •Bilirubin no greater than ULN
- •Creatinine no greater than 1.5 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and for 4 weeks after study
- •HIV negative
- •No AIDS or HIV-1-associated complex
- •No other serious illness
- •No serious active infections
- •No sensory neuropathy greater than grade 1
- •No prior seizures or concurrent potential risk factors for the development of seizures
- •No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •See Disease Characteristics
- •At least 21 days since prior biologic therapy or immunotherapy in the adjuvant or metastatic setting and recovered
- •No concurrent filgrastim (G-CSF)
- •No other concurrent biologic therapy
- •Chemotherapy:
- •See Disease Characteristics
- •At least 21 days since prior chemotherapy in the adjuvant or metastatic setting and recovered
- •No concurrent chemotherapy
- •Endocrine therapy:
- •See Disease Characteristics
- •At least 21 days since prior hormonal therapy in the adjuvant or metastatic setting and recovered
- •No concurrent hormonal therapy
- •No concurrent systemic steroids (including creams)
- •Radiotherapy:
- •See Disease Characteristics
- •At least 21 days since prior radiotherapy and recovered
- •Prior radiotherapy to all known sites of disease allowed if there is objective evidence of progression
- •No concurrent radiotherapy
- •See Disease Characteristics
- 另有 8 项未显示
排除标准
- 未提供
研究者
研究点 (94)
Loading locations...
相似试验
Unknown
2 期
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00027664Cancer Research UK90
已完成
3 期
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney CancerKidney CancerNCT00005966Eastern Cooperative Oncology Group
Unknown
2 期
Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone SarcomaSarcomaNCT00026416Herbert Irving Comprehensive Cancer Center
已完成
3 期
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00002737European Organisation for Research and Treatment of Cancer - EORTC320
已完成
3 期
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With MelanomaMelanoma (Skin)NCT00006237SWOG Cancer Research Network432